Literature DB >> 10975965

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

S S Ellenberg1, R Temple.   

Abstract

Placebo controls are commonly used in clinical trials of investigational treatments because they have important advantages. In recent years, some have criticized the use of placebo-controlled trials when effective alternative therapy exists, regardless of the expected effect of the therapy. In part 1 of this paper, ethical arguments are addressed and the interpretive problems inherent in the use of active-control equivalence trials to establish efficacy of a new treatment are clarified. However, uncertainties may complicate decisions about appropriate use of placebo controls in some situations. Part 2 discusses more fully the ethical considerations for using placebo controls in particular medical settings. The value and relevance of placebo-controlled trials of new agents in situations in which proven effective therapy is available are also explored.

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  2000        PMID: 10975965     DOI: 10.7326/0003-4819-133-6-200009190-00015

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  53 in total

1.  Declaration of Helsinki should be strengthened. Equipoise is essential principle of human experimentation.

Authors:  R J Lilford; B Djulbegovic
Journal:  BMJ       Date:  2001-02-03

Review 2.  Benefits and burdens of placebos in psychiatric research.

Authors:  Scott Y H Kim
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

3.  A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?

Authors:  Suzanne Hill; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Randomized trials in oncology: a fertile ground for controversy.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 5.  Current epistemological problems in evidence based medicine.

Authors:  R E Ashcroft
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

6.  The standard of care debate: the Declaration of Helsinki versus the international consensus opinion.

Authors:  R K Lie; E Emanuel; C Grady; D Wendler
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

Review 7.  Informed consent and the use of placebo in Poland: ethical and legal aspects.

Authors:  Piotr Zaborowski; Adam Górski
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

Review 8.  Using empirical data to inform the ethical evaluation of placebo controlled trials.

Authors:  Jeremy Sugarman
Journal:  Sci Eng Ethics       Date:  2004-01       Impact factor: 3.525

9.  The dawn of pediatric personalized therapeutics.

Authors:  Stephen P Spielberg
Journal:  J Pediatr Pharmacol Ther       Date:  2010-01

Review 10.  Understanding equivalence and noninferiority testing.

Authors:  Esteban Walker; Amy S Nowacki
Journal:  J Gen Intern Med       Date:  2010-09-21       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.